Pasar al contenido principal

NUEVOS ANALOGOS DE CONTILISANT: DISEÑO, SINTESIS Y EVALUACION BIOLOGICA

PID2019-105813RB-C22

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE ALCALA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity in Neurodegenerative Diseases

  • Toledano-Pinedo, Mireia
  • Porro-Pérez, Alicia
  • Schäker-Hübner, L.
  • Romero, Fernando
  • Dong, M.
  • Samadi, A.
  • Almendros, Pedro
  • Iriepa, I.
  • Bautista-Aguilera, O. M.
  • Rodríguez-Fernández, M. M.
  • Solana-Manrique, C.
  • Sanchis, I.
  • Mora-Morell, A.
  • Rodríguez, A. C.
  • Sánchez-Pérez, A. M.
  • Knez, D.
  • Gobec, S.
  • Bellver-Sanchis, A.
  • Pérez, B.
  • Dobrydnev, A. V.
  • Artetxe-Zurutuza, A.
  • Matheu, A.
  • Siwek, A.
  • Wolak, M.
  • Satała, G.
  • Bojarski, A. J.
  • Doroz-Płonka, Agata
  • Handzlik, J.
  • Godyń, J.
  • Więckowska, A.
  • Paricio, N.
  • Griñán-Ferré, C.
  • Hansen, F. K.
  • Marco-Contelles, José
Herein, we describe the design, synthesis, and biological evaluation of 15 Contilisant+Tubastatin A hybrids. These ligands are polyfunctionalized indole derivatives developed by juxtaposing selected pharmacophoric moieties of Contilisant and Tubastatin A to act as multifunctional ligands. Compounds 3 and 4 were identified as potent HDAC6 inhibitors (IC = 0.012 μM and 0.035 μM, respectively), so they were further evaluated in Drosophila and human cell models of Parkinson’s disease (PD). Both compounds attenuated PD-like phenotypes, such as motor defects, oxidative stress, and mitochondrial dysfunction in PD model flies. Ligands 3 and 4 were also studied in the transgenic Caenorhabditis elegans CL2006 model of Alzheimer’s disease (AD). Both compounds were nontoxic, did not induce undesirable animal functional changes, inhibited age-related paralysis, and improved cognition in the thrashing assay. These results highlight 3 and 4 as novel multifunctional ligands that improve the features of PD and AD hallmarks in the respective animal models., JMC thanks AEI (Government of Spain; Grant PID2019-105813RB-C21) and UCJC [Grant: “In vivo analysis of new analogues of Contilisant (MITOPI) (2022)”] for support. This work is part of the MINA-CM program (number S2022/BMD-7236), funded by the call for the implementation of programs of R&D activities between research groups of the Community of Madrid in Biomedicine 2022 (Order 1171/2022). MTP thanks MINA- CM program (number S2022/BMD-7236) for a contract. MMRF and AP thank Comunidad de Madrid for a “Investigo” Contract (2022-23). II thanks AEI (Government of Spain; Grant PID2019-105813RB-C22) for support. AS thanks the UAEU for financial support by Strategic Research Program-Zayed Center for Health Sciences (Grant # G00003680) and by the SURE PLUS (grant #: G00003976) (2022). CGF thanks AEI (MINECO-FEDER, Government of Spain; Grant PID2022-139016OA-I00), Generalitat de Catalunya (Grant 2021 SGR 00357), and AGAUR (Grant 2023Llavor005). ABS acknowledges the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) for her FI-SDUR fellowship (2021FISDU 00182). Some strains were provided by the CGC, which is funded by NIH Office of Research Infrastructure Programs (P40 OD010440). DK and SG thank the Slovenian Research and Innovation Agency (Research Core Funding grant P1-0208, and project J1-3018) for finnancial support. LSH wants to greatfully acknowledge experimental support by Philipp Stegen.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Contilistat, a New Multitarget Small Polyfunctionalized Indole Derivative

  • Toledano-Pinedo, Mireia
  • Diez-Iriepa, Daniel
  • Porro-Pérez, Alicia
  • Schäker-Hübner, Linda
  • Hanl, Maria
  • Samadi, Abdelouahid
  • Almendros, Pedro
  • Iriepa, Isabel
  • Rodríguez-Fernández, M. Mercedes
  • Griñán-Ferré, Christian
  • Siwek, Agata
  • Wolak, Małgorzata
  • Satała, Grzegorz
  • Bojarski, Andrzej J.
  • Doroż-Płonka, Agata
  • Handzlik, Jadwiga
  • Godyń, Justyna
  • Knez, Damijan
  • Gobec, Stanislav
  • Więckowska, Anna
  • Hansen, Finn K.
  • Marco-Contelles, José
We describe the design, synthesis, and in vitro biological evaluation of contilistat, a novel polyfunctionalized indole derivative designed as a hybrid of contilisant and vorinostat containing key pharmacophoric groups of both parent ligands., J.M.C. thanks AEI (Government of Spain; Grant PID2019-105813RB- C21) and UCJC [Grant: In vivo analysis of new analogues of contilisant (MITOPI) (2022)] for support. M.M.R.F. and A.P. thank Comunidad de Madrid for an Investigo Contract (2022–23). I.I. thanks AEI (Govern- ment of Spain; Grant PID2019-105813RB-C22) for support. D.D.I. thanks the Spanish Ministry of Science, Innovation, and Universities for a predoctoral FPU grant. A.S. and D.D.I. thank the UAEU for finan- cial support by the Strategic Research Program–Zayed Center for Health Sciences (G00003680) and SURE PLUS grant (G00003976) (2022). The research was partly supported by Jageillonian University (project no. N42/DBS/000331). Financial support from the Slovenian Research and Innovation Agency (Research Core Funding grant P1- 0208) is gratefully acknowledged. This research was also supported by the Ministry of Education, Science, and Sport (MIZŠ) and the Euro- pean Regional Development Fund OP20.05187 RI-SI-EATRIS. L.S.H., M.H., and F.K.H. acknowledge partial funding from the Deutsche For- schungsgemeinschaft [GRK2873 (494832089)].FundingInformati, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-based Therapy of Parkinson’s Disease

  • Toledano-Pinedo, Mireia
  • Porro-Pérez, Alicia
  • Schäker-Hübner, Linda
  • Diez-Iriepa, Daniel
  • Iriepa, Isabel
  • Siwek, Agata
  • Wolak, Małgorzata
  • Satała, Grzegorz
  • Bojarski, Andrzej J.
  • Doroz-Płonka, Agata
  • Handzlik, Jadwiga
  • Godyń, Justyna
  • Dallemagne, Patrick
  • Rochais, Christophe
  • Davis, Audrey
  • Since, Marc
  • Pérez, Belén
  • Bellver-Sanchis, Aina
  • Irisarri, Alba
  • Pallàs, Mercè
  • Solana-Manrique, Cristina
  • López-Muñoz, Francisco
  • Ismaili, Lhassane
  • Griñán-Ferré, Christian
  • Paricio, Nuria
  • K. Hansen, Finn
  • Więckowska, Anna
  • Marco-Contelles, José
This article belongs to the Special Issue 25th Anniversary of IJMS: Updates and Advances in Molecular Pathology, Diagnostics, and Therapeutics, Herein, we have identified the polyfunctionalized 1-(phenylsulfonyl)-1H-indole-2-carboxylic acid derivative MTP150 for the treatment of neurodegenerative diseases owing to its efficacy in reducing protein aggregation, modulating matrix metalloproteinase activity, mitigating neuroinflammation, and enhancing DNA damage repair pathways across in vivo Caenorhabditis elegans models of Alzheimer’s disease, Parkinson’s disease (PD), and Huntington’s disease. Further experiments in an in vivo Drosophila model of PD showed that MTP150 increased motor performance, reduced oxidative stress levels, and restored mitochondrial function in model flies. In addition, MTP150 exhibited neuroprotective effects in PD model cells, thereby supporting its therapeutic potential for this disease., J.M.-C. thanks AEI (Government of Spain; Grant PID2019-105813RB-C21) and Comunidad de Madrid (IND2023/BMD-27036) for support. I.I. thanks AEI (Government of Spain; Grant PID2019-105813RB-C22) for support. A.P.-P. is grateful to Comunidad de Madrid (IND2023/BMD27036) for a fellowship. This work was supported by grants PID2022-139016OA-I00 and PDC2022-133441-I00, funded by MICIU/AEI/10.13039/501100011033 and FEDER, UE, awarded to C.G.-F. and M.P.; Generalitat de Catalunya (2021 SGR 00357) to CGF and MP; and University of Valencia (UVINV-AE-3664989) to NP. This study was co-financed by Secretaria d’Universitats i Recerca de Departament d’Empresa i Coneixement de la Generalitat de Catalunya 2022 (Producte 0092; Llavor 005 and 007; to CGF). The work of L.S.-H. and F.K.H. was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), GRK2873 (494832089)., Peer reviewed
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity in Neurodegenerative Diseases

  • Toledano Pinedo, Mireia
  • Porro Pérez, Alicia
  • Paricio, Nuria
  • Griñan Ferré, Christian
  • Hanssen, Finn
  • Schaker-Hubner, Linda
  • Romero, Fernando
  • Dong, Ming
  • Samadi, Abdelouahid
  • Almendros, Pedro
  • Iriepa Canalda, Isabel|||0000-0003-3475-9624
  • Bautista Aguilera, Óscar Mauricio|||0000-0002-1327-1681
  • Rodríguez Fernández, M. Mercedes
  • Marco Contelles, José Luis
Herein, we describe the design, synthesis, and biological evaluation of 15 Contilisant+Tubastatin A hybrids. These ligands are polyfunctionalized indole derivatives developed by juxtaposing selected pharmacophoric moieties of Contilisant and Tubastatin A to act as multifunctional ligands. Compounds 3 and 4 were identified as potent HDAC6 inhibitors (IC50 = 0.012 mu M and 0.035 mu M, respectively), so they were further evaluated in Drosophila and human cell models of Parkinson's disease (PD). Both compounds attenuated PD-like phenotypes, such as motor defects, oxidative stress, and mitochondrial dysfunction in PD model flies. Ligands 3 and 4 were also studied in the transgenic Caenorhabditis elegans CL2006 model of Alzheimer's disease (AD). Both compounds were nontoxic, did not induce undesirable animal functional changes, inhibited age-related paralysis, and improved cognition in the thrashing assay. These results highlight 3 and 4 as novel multifunctional ligands that improve the features of PD and AD hallmarks in the respective animal models., Ministerio de Ciencia, Innovación y Universidades